NO20040484L - Vandig dispersjon som omfatter stabile nanopartikler av en vannuloselig forbindelse og en eksipient slik som triglyserider med middels kjedelengde (MCT). - Google Patents

Vandig dispersjon som omfatter stabile nanopartikler av en vannuloselig forbindelse og en eksipient slik som triglyserider med middels kjedelengde (MCT).

Info

Publication number
NO20040484L
NO20040484L NO20040484A NO20040484A NO20040484L NO 20040484 L NO20040484 L NO 20040484L NO 20040484 A NO20040484 A NO 20040484A NO 20040484 A NO20040484 A NO 20040484A NO 20040484 L NO20040484 L NO 20040484L
Authority
NO
Norway
Prior art keywords
water
mct
excipient
aqueous dispersion
chain length
Prior art date
Application number
NO20040484A
Other languages
English (en)
Norwegian (no)
Inventor
Pia Margaretha Cecilia Hedberg
Urban Tommy Skantze
Lars Christian Von Corswant
Anna Elisabeth Zackrisson
Per Lennart Lindfors
Ulf Olsson
Original Assignee
Astrazeneca Ab Global Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0119081A external-priority patent/GB0119081D0/en
Priority claimed from GB0212463A external-priority patent/GB0212463D0/en
Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip
Publication of NO20040484L publication Critical patent/NO20040484L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dental Preparations (AREA)
NO20040484A 2001-08-06 2004-02-03 Vandig dispersjon som omfatter stabile nanopartikler av en vannuloselig forbindelse og en eksipient slik som triglyserider med middels kjedelengde (MCT). NO20040484L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0119081A GB0119081D0 (en) 2001-08-06 2001-08-06 Process
GB0212463A GB0212463D0 (en) 2002-05-30 2002-05-30 Process
PCT/GB2002/003583 WO2003013472A1 (fr) 2001-08-06 2002-08-01 Dispersion aqueuse comprenant des nanoparticules stables d'un triglyceride a chaine moyenne (mtc) insoluble dans l'eau actif et d'un triglyceride a chaine moyenne de type excipient

Publications (1)

Publication Number Publication Date
NO20040484L true NO20040484L (no) 2004-03-31

Family

ID=26246405

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040484A NO20040484L (no) 2001-08-06 2004-02-03 Vandig dispersjon som omfatter stabile nanopartikler av en vannuloselig forbindelse og en eksipient slik som triglyserider med middels kjedelengde (MCT).

Country Status (20)

Country Link
US (1) US20050009908A1 (fr)
EP (1) EP1416917B1 (fr)
JP (1) JP4714412B2 (fr)
KR (1) KR100914113B1 (fr)
CN (1) CN1254233C (fr)
AT (1) ATE365537T1 (fr)
AU (1) AU2002317409B2 (fr)
BR (1) BR0211705A (fr)
CA (1) CA2456180C (fr)
CY (1) CY1107059T1 (fr)
DE (1) DE60220923T2 (fr)
DK (1) DK1416917T3 (fr)
ES (1) ES2287293T3 (fr)
HK (1) HK1064048A1 (fr)
IL (2) IL160103A0 (fr)
MX (1) MXPA04001071A (fr)
NO (1) NO20040484L (fr)
NZ (1) NZ530916A (fr)
PT (1) PT1416917E (fr)
WO (1) WO2003013472A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
AU2004247615B2 (en) * 2003-06-18 2008-02-21 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as CB1 modulators
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
US20080193534A1 (en) * 2005-08-12 2008-08-14 Astrazeneca Ab Process
EP2054036B1 (fr) * 2006-07-24 2019-12-18 Singh-Broemer and Company, Inc. Formulation de nanoparticules solides de substances pharmaceutiques insolubles dans l'eau avec mûrissement d'ostwald réduit
US20100260691A1 (en) * 2006-07-31 2010-10-14 Narayanan Kolazi S Aqueous compositions containing a hydrophobic material
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
JP2010517759A (ja) * 2007-02-09 2010-05-27 アストラゼネカ・アクチエボラーグ 水性媒体中における固体非晶質サブミクロン粒子の安定な分散体を製造する方法
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
EP2178893A4 (fr) * 2007-07-16 2012-09-19 Poniard Pharmaceuticals Inc Formulations orales pour du picoplatine
JP2011511071A (ja) * 2008-02-08 2011-04-07 ポニアード ファーマシューティカルズ， インコーポレイテッド 肺癌を治療するためのピコプラチンおよびアムルビシン
BRPI1004808B1 (pt) * 2010-10-27 2020-09-29 Embrapa - Empresa Brasileira De Pesquisa Agropecuária Composições baseadas em nanopartículas de própolis, processos de obtenção e uso
AU2013225982B2 (en) 2012-02-29 2017-11-30 Pulmatrix, Inc. Inhalable dry powders
KR102045732B1 (ko) * 2012-12-28 2019-11-18 엘지디스플레이 주식회사 온도감응형 계면활성제를 이용한 수용성 나노입자의 제조방법
PT106738B (pt) 2013-01-09 2015-06-08 Hovione Farmaciencia Sa Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico
JP2016507542A (ja) * 2013-02-08 2016-03-10 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 反応型噴霧乾燥による無機／有機複合材料の製造
US20190110993A1 (en) * 2017-09-12 2019-04-18 Raj Selvaraj Solid Nanoparticle Formulation of Water Insoluble Pharmaceutical Substances with Reduced Ostwald Ripening
AU2022381536A1 (en) 2021-11-05 2024-05-02 Cinclus Pharma Holding AB (publ) Polymorphs of the hydrochloride salt of linaprazan glurate

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2224133B2 (de) * 1972-05-17 1974-06-20 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von bestimmten Mikroorganismen-Stämmen zur Gewinnung von Cholesterinoxydase, welche Cholesterin mit O tief 2 zu Cholestenon + H tief 2 O tief 2 oxydiert
US4348385A (en) * 1980-11-17 1982-09-07 Mobay Chemical Corporation Flowable pesticides
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
US4799962A (en) * 1987-12-24 1989-01-24 Aqualon Company Water-soluble polymer dispersion
US5145648A (en) * 1988-06-28 1992-09-08 Matsushita Electric Industrial Co., Ltd. Exhaust smoke purifier apparatus
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
IE67187B1 (en) * 1990-06-15 1996-03-06 Merck & Co Inc A crystallization method to improve crystal structure and size
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ATE137962T1 (de) * 1991-12-05 1996-06-15 Alfatec Pharma Gmbh Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5468604A (en) * 1992-11-18 1995-11-21 Eastman Kodak Company Photographic dispersion
GB9319129D0 (en) * 1993-09-15 1993-11-03 Dowelanco Ltd Storage and dilution of stable aqueous dispersions
SE9303281D0 (sv) * 1993-10-07 1993-10-07 Astra Ab New formulation
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
DK0951280T3 (da) * 1996-10-03 2004-05-17 Hermes Biosciences Inc Hydrofile mikropartikler og fremgangsmåder til fremstilling heraf
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations

Also Published As

Publication number Publication date
KR100914113B1 (ko) 2009-08-27
IL160103A (en) 2008-11-26
CA2456180C (fr) 2011-10-11
ES2287293T3 (es) 2007-12-16
EP1416917A1 (fr) 2004-05-12
DE60220923T2 (de) 2008-03-06
JP4714412B2 (ja) 2011-06-29
CA2456180A1 (fr) 2003-02-20
DE60220923D1 (de) 2007-08-09
EP1416917B1 (fr) 2007-06-27
ATE365537T1 (de) 2007-07-15
WO2003013472A1 (fr) 2003-02-20
MXPA04001071A (es) 2004-05-20
HK1064048A1 (en) 2005-01-21
CN1254233C (zh) 2006-05-03
BR0211705A (pt) 2004-09-28
US20050009908A1 (en) 2005-01-13
AU2002317409B2 (en) 2007-06-21
PT1416917E (pt) 2007-08-16
KR20040025739A (ko) 2004-03-25
DK1416917T3 (da) 2007-09-17
CN1564677A (zh) 2005-01-12
IL160103A0 (en) 2004-06-20
NZ530916A (en) 2005-07-29
CY1107059T1 (el) 2012-10-24
JP2005500362A (ja) 2005-01-06

Similar Documents

Publication Publication Date Title
NO20040484L (no) Vandig dispersjon som omfatter stabile nanopartikler av en vannuloselig forbindelse og en eksipient slik som triglyserider med middels kjedelengde (MCT).
EP2241308A3 (fr) Procédé de revêtement de particules fines avec un film de lipides
SE0004620D0 (sv) Processes to generate submicron particles of waterinsoluble componunds
WO2002096457A3 (fr) Formulations liquides stable s
CY1108130T1 (el) Σταθεροποιηση των δραστικων παραγοντων μεσω τυποποιημενης παρασκευης σε μορφη νανοσυσσωματωματος
CO5670354A2 (es) Proceso para la elaboracion de aripiprazol esteril de tamaño particula promedio deseado
CY1111817T1 (el) Απομακρυνση του διαλυτη με μια διαδικασια προσθιας οσμωσης
NO20054908L (no) Fremgangsmate for findeling og stabilisering av sma partikler i suspensjon
AU2002212412A1 (en) Method for making very fine particles consisting of a principle inserted in a host molecule
BR0304937B1 (pt) composição de antiespumante de silicone encapsulado e processo para a produção de uma composição de antiespumante de silicone encapsulado.
ATE399566T1 (de) Stabile dispersion fester teilchen mit einer wasserunlöslichen pyrazin-verbindung
WO2001062088A3 (fr) Procede de traitement de plantes et d'amelioration de la croissance des plantes et de phytoprotection de fortes concentrations de photocatalyseurs pour l'utilisation de polyacylglycosides et/ou de polyalkylglycosides et formulations de mise en oeuvre
ATE449643T1 (de) Verfahren zur stabilisierung von peroxycarbonsäuren in tensidhaltigen dispersionen
ATE440594T1 (de) Herstellung von kolloidale teilchen enthaltenden pulvern
WO2003066019A3 (fr) Procede de production de poudres seches dispersibles dans l'eau a partir de composes difficilement solubles dans l'eau
BR0209115B1 (pt) Composição granular e processo para sua produção
AU6924501A (en) Method for isolating and purifying a protein and resulting protein
AU2002318846A1 (en) Method of crystallizing reduced coenzyme Q10 from aqueous solution
ATE484607T1 (de) Mikrowellenplasmaverarbeitungsverfahren
ITSA20030013A1 (it) Manufatti microporosi e nanoporosi a base di
ES2183522T3 (es) Cristalizacion de lactitol, producto de lactitol cristalino y utilizacion del mismo.
TW200635613A (en) Water-soluble cosmetic composition and method for manufacturing the same
BR0003166A (pt) Processo para estabilização de compostos antioxidantes, e composições aquosas
WO2004050889A3 (fr) Production de derives de flavonoides
WO2005097058A3 (fr) Compositions pharmaceutiques de pyrimidine-2,4,6-triones

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application